Circulating tumor necrosis factor (TNF)-α and soluble TNF-α receptors in patients with Guillain-Barré syndrome

Guillain-Barré syndrome (GBS) is an inflammatory disorder that may implicate proinflammatory cytokines such as TNF-α in its pathogenesis. We determined serum levels of TNF-α and the specific antagonists sTNF-Rs p55 and p75 in 24 patients with GBS at days 1, 15 and 30 of hospitalization. Patients were in the progression phase of the disease at day 1, and in the recovery phase at day 30. They were classified as able to walk (stage A), confined to bed (B), or under assisted ventilation (C). All patients underwent plasma exchange within day 1–12. At day 1, TNF-α levels were elevated in

Full-size image

patients, and sTNF-Rs were elevated in

Full-size image

. TNF-α levels had not decreased at day 15, and dropped at day 30 (p < 0.04), whereas sTNF-R p55 remained elevated at day 15 and day 30. The TNF-α/sTNF-Rs ratio, estimating active TNF-α unbound to sTNF-Rs, decreased from day 1 to day 30 (p < 0.05). A positive correlation was found between disease severity and sTNF-Rs serum levels (p < 0.01). In conclusion, elevated circulating sTNF-Rs assesses activation of the TNF-α system in almost all patients with GBS and correlates positively with disease severity. Drop of TNF-α contrasting with sustained elevation of sTNF-R p55 during recovery suggests that sTNF-R p55 may be important in the fading of the neural inflammatory effect of TNF-α in GBS.